{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T11:44:39Z","timestamp":1786189479590,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04724-2","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T11:28:06Z","timestamp":1786188486000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Deciphering the immune landscape of parathyroid carcinoma: implications for immunotherapeutic responsiveness"],"prefix":"10.1007","volume":"91","author":[{"given":"Saransh","family":"Kanaujia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0660-9939","authenticated-orcid":false,"given":"Md Ali","family":"Osama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayati","family":"Sarangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumitra Dey","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyaz Ahmad","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Kataria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Millo","family":"Tabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7037-4444","authenticated-orcid":false,"given":"Shipra","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"issue":"4","key":"4724_CR1","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12022-024-09832-1","volume":"35","author":"M Boruah","year":"2024","unstructured":"M. Boruah, S. Agarwal, R.A. Mir, S.D. Choudhury, K. Sikka, S. Rastogi, N. Damle, M.C. Sharma, Unravelling the reasons behind limited response to anti-PD therapy in ATC: a comprehensive evaluation of tumor-infiltrating immune cells and checkpoints. Endocr. Pathol. (2024). https:\/\/doi.org\/10.1007\/s12022-024-09832-1","journal-title":"Endocr. Pathol."},{"key":"4724_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp-2025-210585","author":"M Boruah","year":"2026","unstructured":"M. Boruah, S. Agarwal, R.A. Mir, C.A. Singh, R. Kumar, K. Sikka, K. Kataria, Myeloid-derived suppressor cells in anaplastic thyroid carcinoma: insights from prospective immune profiling and implications for targeted immunotherapy. J. Clin. Pathol. (2026). https:\/\/doi.org\/10.1136\/jcp-2025-210585","journal-title":"J. Clin. Pathol."},{"key":"4724_CR3","doi-asserted-by":"publisher","unstructured":"S. Agarwal, C.K. Jung, P. Gaddam, M. Hirokawa, T. Higashiyama, J.F. Hang, W.A. Lai, S. Keelawat, Z. Liu, H.Y. Na et al., PD-L1 Expression and Its Modulating Factors in Anaplastic Thyroid Carcinoma: A Multi-institutional Study. Am. J. Surg. Pathol. 48(10), 1233\u20131244 (2024). https:\/\/doi.org\/10.1097\/PAS.0000000000002284","DOI":"10.1097\/PAS.0000000000002284"},{"key":"4724_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116203","volume":"171","author":"JW Cui","year":"2024","unstructured":"J.W. Cui, Y. Li, Y. Yang, H.K. Yang, J.M. Dong, Z.H. Xiao, X. He, J.H. Guo, R.Q. Wang, B. Dai, et al., Tumor immunotherapy resistance: revealing the mechanism of PD-1\/PD-L1-mediated tumor immune escape. Biomed. Pharmacother. (2024). https:\/\/doi.org\/10.1016\/j.biopha.2024.116203","journal-title":"Biomed. Pharmacother"},{"issue":"17","key":"4724_CR5","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","volume":"27","author":"L Marcus","year":"2021","unstructured":"L. Marcus, L.A. Fashoyin-Aje, M. Donoghue, M. Yuan, L. Rodriguez, P.S. Gallagher, R. Philip, S. Ghosh, M.R. Theoret, J.A. Beaver, et al., FDA approval summary: pembrolizumab for the treatment of tumor mutational burden\u2013high solid tumors. Clin. Cancer Res. (2021). https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0327","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"4724_CR6","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126908","volume":"4","author":"M Yarchoan","year":"2019","unstructured":"M. Yarchoan, L.A. Albacker, A.C. Hopkins, M. Montesion, K. Murugesan, T.T. Vithayathil, N. Zaidi, N.S. Azad, D.A. Laheru, G.M. Frampton, et al., PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight. (2019). https:\/\/doi.org\/10.1172\/jci.insight.126908","journal-title":"JCI Insight"},{"issue":"1","key":"4724_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00449-4","volume":"6","author":"T Tang","year":"2021","unstructured":"T. Tang, X. Huang, G. Zhang, Z. Hong, X. Bai, T. Liang, Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal. Transduct. Target. Ther. (2021). https:\/\/doi.org\/10.1038\/s41392-020-00449-4","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"7","key":"4724_CR8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41573-022-00493-5","volume":"21","author":"TK Kim","year":"2022","unstructured":"T.K. Kim, E.N. Vandsemb, R.S. Herbst, L. Chen, Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat. Rev. Drug Discov. (2022). https:\/\/doi.org\/10.1038\/s41573-022-00493-5","journal-title":"Nat. Rev. Drug Discov"},{"issue":"6","key":"4724_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061426","volume":"14","author":"A Ullah","year":"2022","unstructured":"A. Ullah, J. Khan, A. Waheed, N. Sharma, E.K. Pryor, T.R. Stumpe, L. Velasquez Zarate, F.D. Cason, S. Kumar, S. Misra, et al., Parathyroid carcinoma: incidence, survival analysis, and management: a study from the SEER database and insights into future therapeutic perspectives. Cancers (Basel). (2022). https:\/\/doi.org\/10.3390\/cancers14061426","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4724_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s12022-022-09709-1","volume":"33","author":"LA Erickson","year":"2022","unstructured":"L.A. Erickson, O. Mete, C.C. Juhlin, A. Perren, A.J. Gill, Overview of the 2022 WHO classification of parathyroid tumors. Endocr. Pathol. (2022). https:\/\/doi.org\/10.1007\/s12022-022-09709-1","journal-title":"Endocr. Pathol."},{"issue":"2","key":"4724_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40618-021-01646-w","volume":"45","author":"S Agarwal","year":"2022","unstructured":"S. Agarwal, S. Kardam, P. Chatterjee, C. Kumar, M. Boruah, M.C. Sharma, M. Tabin, L. Ramakrishnan, CaSR expression in normal parathyroid and PHPT: new insights into pathogenesis from an autopsy-based study. J. Endocrinol. Invest. (2022). https:\/\/doi.org\/10.1007\/s40618-021-01646-w","journal-title":"J. Endocrinol. Invest."},{"issue":"2","key":"4724_CR12","doi-asserted-by":"publisher","first-page":"312","DOI":"10.4103\/jcrt.jcrt_1471_22","volume":"19","author":"M Boruah","year":"2023","unstructured":"M. Boruah, P. Gaddam, S. Agarwal, R.A. Mir, R. Gupta, M.C. Sharma, S.V. Deo, N. Nilima, PD-L1 expression in rare and aggressive thyroid cancers: a preliminary investigation for a role of immunotherapy. J. Cancer Res. Ther. (2023). https:\/\/doi.org\/10.4103\/jcrt.jcrt_1471_22","journal-title":"J. Cancer Res. Ther."},{"issue":"2","key":"4724_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.pathol.2020.10.007","volume":"53","author":"EC Paver","year":"2021","unstructured":"E.C. Paver, W.A. Cooper, A.J. Colebatch, P.M. Ferguson, S.K. Hill, T. Lum, J.S. Shin, S. O\u2019Toole, L. Anderson, R.A. Scolyer, R. Gupta, Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology. 53(2), 141\u2013156 (2021). https:\/\/doi.org\/10.1016\/j.pathol.2020.10.007","journal-title":"Pathology"},{"issue":"37","key":"4724_CR14","doi-asserted-by":"publisher","first-page":"61618","DOI":"10.18632\/oncotarget.18651","volume":"8","author":"H Ishii","year":"2017","unstructured":"H. Ishii, K. Azuma, A. Kawahara, N. Matsuo, T. Tokito, T. Kinoshita, K. Yamada, T. Sasada, J. Akiba, T. Hoshino, Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy. Oncotarget. (2017). https:\/\/doi.org\/10.18632\/oncotarget.18651","journal-title":"Oncotarget"},{"issue":"7","key":"4724_CR15","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1530\/ec-19-0163","volume":"8","author":"B Pan","year":"2019","unstructured":"B. Pan, A. Wang, J. Pang, Y. Zhang, M. Cui, J. Sun, Z. Liang, Programmed death ligand 1 (PD-L1) expression in parathyroid tumors. Endocr. Connect. (2019). https:\/\/doi.org\/10.1530\/ec-19-0163","journal-title":"Endocr. Connect."},{"issue":"4","key":"4724_CR16","doi-asserted-by":"publisher","first-page":"383","DOI":"10.4183\/aeb.2016.383","volume":"12","author":"X Du","year":"2016","unstructured":"X. Du, L. Wang, B. Shen, H. He, H. Chang, B. Wei, Clinical significance of PD-L1 expression in parathyroid cancer. Acta Endocrinol. (Buchar). (2016). https:\/\/doi.org\/10.4183\/aeb.2016.383","journal-title":"Acta Endocrinol. (Buchar)"},{"key":"4724_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4172\/2472-4971.1000166","volume":"3","author":"AM Silva-Figueroa","year":"2018","unstructured":"A.M. Silva-Figueroa, N.D. Perrier, Parathyroid Carcinoma has a PD-L1 Expression, and Share with Atypical Neoplasms an Abundant Intratumoral Macrophagic Infiltration - A Short Commentary. J. Med. Surg. Pathol. 3, 167 (2018)","journal-title":"J. Med. Surg. Pathol."},{"issue":"10","key":"4724_CR18","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1007\/s40618-020-01224-6","volume":"43","author":"Y Hu","year":"2020","unstructured":"Y. Hu, M. Cui, Y. Bi, X. Zhang, M. Wang, S. Hua, Q. Liao, Y. Zhao, Immunocyte density in parathyroid carcinoma is correlated with disease relapse. J. Endocrinol. Invest. (2020). https:\/\/doi.org\/10.1007\/s40618-020-01224-6","journal-title":"J. Endocrinol. Invest."},{"key":"4724_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.964442","volume":"13","author":"Q Tang","year":"2022","unstructured":"Q. Tang, Y. Chen, X. Li, S. Long, Y. Shi, Y. Yu, W. Wu, L. Han, S. Wang, The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front. Immunol. (2022). https:\/\/doi.org\/10.3389\/fimmu.2022.964442","journal-title":"Front. Immunol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04724-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04724-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04724-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T11:28:06Z","timestamp":1786188486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04724-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4724"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04724-2","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"assertion":[{"value":"15 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Ethics Committee (Ref. No. IECPG-329\/27.04.2022; IEC-570\/02.08.2019).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since archival and anonymised data were used, the requirement for informed consent was waived by the Institutional Ethics Committee.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"260"}}